All In Biotech

Drug Trial Radar · NCT06523400

The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During 26 Weeks of Treatment in Patients With Myotonic Dystrophy Type 1 and Type 2 (Phase 3)

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 176 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

176

Planned (sponsor's estimate)

Start

Feb 13, 2025

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Lupin Ltd.Industry
Sponsor type
Industry
Collaborators
Lupin Atlantis Holdings S.A.
First posted
Jul 26, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Randomized, Double-blind, Placebo-Controlled, Multi-Center Study to Investigate the Efficacy and Safety of Once Daily Mexiletine PR During 26 Weeks of Treatment in Patients with Myotonic Dystrophy Type 1 and Type 2 (HERCULES study) Study website: https://myotonicdystrophystudy.com/

Conditions

  • Myotonic Dystrophy

Interventions

  • Mexiletine granules for prolonged-release oral suspensionDrug

    Mexiletine PR

  • PlaceboDrug

    Matching Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the efficacy of once daily mexiletine PR for the symptomatic treatment of myotonia in patients with myotonic dystrophy type 1 and type 2 (DM1 and DM2).Time frame: 26 weeks

Locations

7 sites in 6 countries. Site status is shown where the registry gives one.

  • Laboratory for Muscle Diseases and Neuropathies

    Leuven, Belgium · Recruiting

  • Aarhus University Hospital

    Aarhus, Denmark · Recruiting

  • Ludug-Maximilians University

    München, Germany · Recruiting

  • Azienda Ospedaliera Universitaria Policlinico Tor Vergata

    Rome, Italy · Recruiting

  • University Hospital of Madrid

    Madrid, Spain · Recruiting

  • Saint George's University Hospitals NHS Foundation Trust

    London, United Kingdom · Recruiting

  • University College Hospital

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.